These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9283904)

  • 1. Does oxypentifylline reduce the intensity of acute graft-versus-host disease following allogeneic bone marrow transplantation?
    Ghosh K; Hutchinson RM
    Haematologia (Budap); 1996; 28(1):45-51. PubMed ID: 9283904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Chan GW; Gorgun G; Miller KB; Foss FM
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
    Byrne JL; Stainer C; Cull G; Haynes AP; Bessell EM; Hale G; Waldmann H; Russell NH
    Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
    Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.
    Takatsuka H; Takemoto Y; Okamoto T; Fujimori Y; Tamura S; Wada H; Okada M; Yamada S; Kanamaru A; Kakishita E
    Bone Marrow Transplant; 1999 Nov; 24(9):1005-7. PubMed ID: 10556960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allogeneic bone marrow transplantation in children from related donors other than HLA-identical siblings].
    Morimoto T; Hattori K; Yabe H; Yabe M; Hinohara T; Shimizu T; Matsumoto M; Hagihara M; Tsuji K; Kato S
    Rinsho Ketsueki; 1998 Sep; 39(9):631-9. PubMed ID: 9796395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences between lymphocyte subsets, after allogeneic bone marrow transplantation, in patients who received tacrolimus and patients who received cyclosporin A.
    Fukuda H; Teshima H; Karasuno T; Hiraoka A; Nakamura H; Masaoka T
    Int J Hematol; 2000 Jan; 71(1):70-4. PubMed ID: 10729997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similarity between eruptions induced by sulfhydryl drugs and acute cutaneous graft-versus-host disease after bone marrow transplantation.
    Takatsuka H; Takemoto Y; Yamada S; Mori A; Wada H; Fujimori Y; Okamoto T; Kanamaru A; Kakishita E
    Hematology; 2002 Feb; 7(1):55-7. PubMed ID: 12171778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.